A positive ANA by HEp-2 indicates antinuclear antibodies are present, meaning the immune system targets nuclear cell components. It’s a sensitive but not specific marker for autoimmune connective‑tissue diseases (for example, lupus, Sjögren’s, scleroderma); titer and staining pattern guide interpretation. Low titers can occur in healthy people, infections, or drug reactions. Further specific antibody tests and clinical correlation are required.

ANA (HEp‑2) positive is a laboratory finding, not a disease; it often indicates autoimmune activity. It's not something that's "cured"—results may persist or sometimes become negative if a trigger (drug, infection) resolves. Management treats the underlying condition and symptoms with immunosuppressive or symptomatic therapies. Prognosis varies by diagnosis and response; consult your clinician for interpretation and follow‑up.

HEp-2 cells are used in ANA testing because this human epithelial cell line provides large, flat nuclei and abundant, well-preserved nuclear and cytoplasmic antigens, increasing sensitivity and enabling visualization of diverse staining patterns. Their consistent antigen expression and morphology allow reproducible, high-sensitivity screening for many autoantibodies linked to systemic autoimmune diseases, guiding subsequent confirmatory testing.

Costs vary widely by country and laboratory. Typical private charges are roughly: India ≈ ₹600–₹2,000; United States ≈ $50–$200; United Kingdom: usually covered by the NHS (no direct patient charge), while private testing runs about £30–£120. Final price depends on the laboratory, whether confirmatory assays are included, and public versus private testing.

Autoimmune hepatitis type 2 is an autoimmune liver disease, usually affecting children and young adults, defined by antibodies such as anti‑LKM1 (and sometimes anti‑LC1). It causes liver inflammation with jaundice, fatigue and raised liver enzymes, and can progress to cirrhosis if untreated. Management requires immunosuppression (typically corticosteroids with or without steroid‑sparing agents) and long‑term follow‑up.

A negative ANA HEp‑2 test makes systemic autoimmune connective‑tissue diseases (like systemic lupus) less likely, but it doesn't absolutely exclude them. Some patients—especially early, limited, or seronegative forms—may test negative. If clinical suspicion remains, clinicians may repeat testing or order specific autoantibodies (ENA, anti‑dsDNA) and investigate other causes of symptoms. Clinical correlation and rheumatology follow‑up are recommended.